Due to rapidly increasing demand for its cardiac cath lab PCI, Diagnostic and Carotid Stenting accreditation and quality review services, ACE is proud to lead the way in offering four new accreditation and external review services for catheter based cardiovascular procedures to include: Congenital Heart Disease, Electrophysiology including Implants & Devices, Transcatheter Valve Therapies and Peripheral Vascular Procedures.

Bristol-Myers Squibb Company and Pfizer Inc.  today announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE (Eliquis evaluated in acute cardioversion coMpared to usuAl treatmeNts for AnTicoagulation in subjEcts with NVAF) assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation (NVAF) undergoing cardioversion.

Two recently published studies on stroke attest to the gains made in controlling hypertension and reducing stroke risk factors—at least in older Americans.

Researchers at Cedars-Sinai Heart Institute in Los Angeles tested a “biological pacemaker” in pig hearts using gene therapy. The approach is at least three years away from human trials, the New York Times reports.

Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European commercial launch of its new 25 mm Lotus Transcatheter Aortic Valve Implantation (TAVI) System, complementing the currently available 23 mm and 27 mm valve sizes.

Stroke patients may be at a greater risk for post-surgical complications, particularly when they had a stroke less than three months prior to surgery, according to a study published July 16 in JAMA. 

Surgery to revise implantable cardioverter-defibrillator (ICD) leads had the highest overall incidence of major complications compared to initial implantation or procedures that did not involve the leads.

The incidence and mortality rates of stroke decreased for elderly men, women, blacks and whites over time for participants in the Atherosclerosis Risk in Communities group, a study published July 16 in JAMA showed. But for younger adults, the incidence trend didn’t carry through.